Rohini Chaudhari

  • Neurorehabilitaion Devices Market Projected to Gain Significant Value by 2027

    Neurorehabilitation Devices Market: Introduction

    Transparency Market Research has published a new report titled, “neurorehabilitation devices market”. According to the report, the global neurorehabilitation devices market was valued at US$ 1.12 Bn in 2018 and is projected to expand at a CAGR of 12.5% from 2019 to 2027. Rise in prevalence of neurological diseases has increased the patient pool undergoing interventional procedures followed by rehabilitation therapies globally, resulting in high demand for neurorehabilitation devices.

    In terms of application, the stroke and Parkinson’s disease segments accounted for major shares of the global neurorehabilitation devices market in 2018. The segments are anticipated to witness strong growth from 2019 to 2027.

    Planning To Lay Down Future Strategy? Request Brochure Of Neurorehabilitaion Devices Market

    https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12791

    The rate of incidence of neurological disorders increases with age. Currently, around 1% of the population above 60 years of age is estimated to be afflicted with Parkinson’s disease across the globe. The incidence rate increases to 5% for people above 85 years of age. Parkinson’s disease is an age-related neurodegenerative disorder that affects large number of people across the globe. It is characterized by muscle contraction, which leads to weakening of physical movement, tremors, muscle rigidity, and gait. It can affect multiple systems of the body. According to the U.S.-based Parkinson’s Foundation, around 7 million to 10 million people are afflicted with Parkinson’s disease across the globe. Around 1 million people in the U.S. suffer from the disease. Around 60,000 people in the U.S. are estimated to be diagnosed with Parkinson’s disease each year.

    Based on product, neurorobotic systems and brain stimulators segments are expected to grow at rapid pace during the forecast period, likely to augment the growth of the neurorehabilitation devices market. Neurorobotic systems and brain stimulators have a wide scope in the neurorehabilitation devices market. These are, however, only a fraction of the different applications being explored in universities, laboratories, and start-up companies for the neurorehabilitation devices.

    Recent advancements in brain-computer interface in the field of neuroscience have been expanded in the development of sophisticated assistive technologies for disability disorders, likely to drive the neurorehabilitation devices market. This technology includes the machine (robot) interfaces of brain computer for connecting patients to computers via electrical signals. This device is primarily used to retain the motor abilities of an individual with disabilities.

    To Obtain All-Inclusive Information On Forecast Analysis Of Neurorehabilitaion Devices Market , Request A Discount

    https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=12791

    The neurorehabilitation devices market is growing rapidly; however, it has few challenges/disadvantages that need to be addressed. A lot of neurorehabilitation devices have failed to address or assist the patient need as per his/her requirements. Hence, it is required to understand how living beings and machines work independently.

    Neurorehabilitation Devices Market: Prominent Regions

    North America held the largest share of the neurorehabilitation devices market in 2018. North America accounted for a significant share of the neurorehabilitation devices market in 2018. The market in the region is likely to grow at a rapid pace during the forecast period. The market in the region is driven by presence of key players, large number of research activities, and a highly structured healthcare industry. Increase in investment by key players in North America and rise in prevalence of neurological disorders are projected to propel the neurorehabilitation devices market in North America.

    The U.S. is projected to dominate the neurorehabilitation devices market in the region during the forecast period, owing to early adoption of technologies such as Ekso Bionics Ekso GT. The country is anticipated to be the most attractive market for neurorehabilitation devices, with high attractiveness index. The neurorehabilitation devices market in the U.S. is expected to expand at a CAGR of ~13% during the forecast period.

    Increase in adoption of neurorehabilitation devices by hospitals, technological advancements, rise in research & development of neurorehabilitation devices for new applications, and surge in demand for rapid and safe neurorehabilitation products drive the neurorehabilitation devices market in the U.S.

    Neurorehabilitation Devices Market: Key Players

    Key players in the neurorehabilitation devices market focus on strengthening their positions in the neurorehabilitation devices market. Players are collaborating with other companies to secure and strengthen their positions in the neurorehabilitation devices market. For instance, in January 2017, Abbott Laboratories acquired St. Jude Medical, a global medical device manufacturer, in order to expand its portfolio.

    Additionally, regulatory approvals is expected to be a major trend in the next few years, leading to advancements and competition in the neurorehabilitation devices market. For Instance, in July 2017, Saebo, Inc. product, SaeboVR, a virtual ADL (activities of daily living) rehabilitation system designed to engage neurological clients in both physical and cognitive challenges involving simulated functional tasks, received the U.S. Food and Drug Administration (FDA) clearance. The SaeboVR is the world’s first FDA-approved ADL-focused virtual reality rehabilitation system, and was made available to clinicians.

    Major players operating in the neurorehabilitation devices market include Bionik Laboratories Corp., Ekso Bionics, DIH Technologies Corporation (Hocoma),Neurostyle Pte Ltd, Saebo, Inc., Neuro Device Group S.A., ReWalk Robotics, Tyromotion GmbH, Boston Scientific Corporation, DIH Technologies Corporation (Hocoma), Reha Technology AG, Medtronic plc, and MindMaze Holding SA.

    More Trending Reports by Transparency Market Research –

    Medical Lifting Slings Market -

    https://www.prnewswire.com/news-releases/rising-geriatric-population-and-their-dependency-on-such-product-to-drive-sales-of-medical-lifting-slings-market-to-us1-350-mn-by-2027-end-finds-tmr-301027400.html

    Request For Coronavirus Infection Market Analysis –

    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16940


  • Proteinuria Therapeutics Market Shares, Strategies, and Forecasts Analysis

    Proteinuria Therapeutics Market: Introduction

    • Proteinuria is also known as albuminuria. It is a condition, in which the amount of protein present in urine is greater than normal. It is usually associated with some form of abnormality or disease, but can be occasionally seen in healthy individuals.
    • Plasma contains several different proteins. One of the most important functions of kidneys is to conserve plasma protein so that it is not removed along with waste products when urine is produced. The two types of tissues that normally inhibit protein from passing into urine are tubules and glomeruli. Proteinuria often occurs when either the tubules or glomeruli in the kidneys are damaged.

    Report Overview @ https://www.transparencymarketresearch.com/proteinuria-therapeutics-market.html

    • Scarring or/and inflammation of the glomeruli can allow increasing amounts of red blood cells (RBCs) and protein to leak into the urine. Damage to the tubules can prevent protein from being reabsorbed.
    • Healthy people can have persistent or temporary proteinuria. Proteinuria can be associated with fever, stress, exposure to cold, and aspirin therapy. The most common reason for protein in the urine is kidney damage due to hypertension and diabetes.
    • Medications such as angiotensin receptor blockers and angiotensin-converting enzyme inhibitors reduce proteinuria

    Planning To Lay Down Future Strategy? Request Brochure Of Proteinuria Therapeutics Market

    https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75849

    Key Drivers of Global Proteinuria Therapeutics Market

    • The global proteinuria therapeutics market is primarily driven by rise in prevalence and incidence of proteinuria across the world
    • According to the National Health and Nutrition Examination Survey (NHANES III- 1988–1994), the prevalence of proteinuria in the U.S. was 9.7% in females and 6.1% in males. The prevalence of proteinuria in patients with diabetes was 28.8%, 16.0% in patients with hypertension, and 5.1% in those without cardiovascular disease, hypertension, diabetes, or elevated serum creatinine level.

    Angiotensin-converting Enzyme (ACE) Inhibitors Segment Held Major Share of Global Market

    • In terms of drug class, the global proteinuria therapeutics market can be divided into angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and others
    • The angiotensin-converting enzyme (ACE) inhibitors segment is anticipated to dominate the global market during the forecast period
    • Angiotensin-converting enzyme (ACE) inhibitors are highly preferred by clinicians and medicine manufacturers. This is anticipated to drive the segment during the forecast period.

    Retail Pharmacies Segment to Offer Attractive Opportunities

    • Based on distribution channel, the global proteinuria therapeutics market can be classified into hospital pharmacies, retail pharmacies, and online pharmacies
    • The retail pharmacies segment is expected to account for major share of the global proteinuria therapeutics market by 2027
    • The segment’s dominance can be attributed to increase in sales of proteinuria therapeutics through retail channel

    To Obtain All-Inclusive Information On Forecast Analysis Of Proteinuria Therapeutics Market , Request A Discount

    https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=75849

    North America to Dominate Global Proteinuria Therapeutics Market

    • In terms of region, the global proteinuria therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global market during the forecast period.
    • Rise in prevalence of various risk factors related to proteinuria and increase in sales of off-label drugs for the treatment of the condition are anticipated to drive the segment during the forecast period.

    Key Players Operating in Global Market

    Key players operating in the global proteinuria therapeutics market are:

    • AbbVie, Inc.
    • AstraZeneca plc
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Co.
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Sanofi
    • Takeda Pharmaceutical Co. Ltd.
    • Teva Pharmaceutical Industries Ltd.

    More Trending Reports by Transparency Market Research –

    ECG Devices Market –

    https://www.prnewswire.com/news-releases/ecg-devices-market-to-gain-us-6-79-billion-by-2026--says-tmr-300813779.html

    Request For Coronavirus Infection Market Analysis –

    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16940


  • Organ Transplant Rejection Medications Market: Business Overview and Global Development Trends

    Organ Transplant Rejection Medications Market: Introduction

    According to the report, the global organ transplant rejection medications market was valued at US$ 4.7 Bn in 2018 and is projected to expand at a CAGR of ~3% from 2019 to 2027. Rise in healthcare spending and improvements in healthcare infrastructure, and increase in the global geriatric population are the major factors anticipated to drive the organ transplant rejection Medication market from 2019 to 2027.

    Rise in Healthcare Spending and Improvement in Healthcare Infrastructure to Drive Global Market

    Increase in patient awareness about personal health boosts the demand for medical devices. Patients are more aware and proactive about their health and are willing to seek a physician's advice at an early stage. Increase in per capita disposable income is encouraging people to spend more on healthcare facilities, which, in turn, fuels the global organ transplant rejection medications market. Advertisements have increased public visibility of new technology, thereby generating interest among chronic patients for organ transplant rejection medications.

    Planning To Lay Down Future Strategy? Request Brochure Of Organ Transplant Rejection Medications Market

    https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=76123

    Changing demographics in emerging economies such as China, India, Brazil, and South Africa are expected to provide significant opportunities for organ transplant rejection medications. Moreover, public and private healthcare expenditure is expected to increase in these countries, which is likely to drive the organ transplant rejection medications market.

    Increase in healthcare expenditure, rise in global per capita income, and improvement in healthcare infrastructure and government reimbursement programs in developed as well as developing countries are likely to propel the organ transplant rejection medications market in the near future.

    Kidney Transplant to Offer Lucrative Opportunities

    The report offers detailed segmentation of the global organ transplant rejection medications market based on drug class, transplant type, distribution channel, and region. In terms of drug class, the organ transplant rejection medications market has been segmented into calcineurin inhibitors, antiproliferative agents, mTOR inhibitors, antibodies, and steroids. Based on transplant type, the market has been segmented into kidney transplant, bone marrow transplant, liver transplant, heart transplant, lung transplant, and other transplants. Kidney transplant is a highly preferred treatment for end-stage renal disease (ESRD). It is comparatively more cost-effective than dialysis and is associated with a long-term mortality improvement.

    Based on distribution channel, the global organ transplant rejection medications market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies. Hospitals are major clinical settings wherein a large number of surgeries are conducted. This makes hospital pharmacies a prominent segment of the organ transplant rejection medications market.

    To Obtain All-Inclusive Information On Forecast Analysis Of Organ Transplant Rejection Medications Market , Request A Discount

    https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=76123

    North America to Lead Organ Transplant Rejection Medications Market

    North America was the largest market for organ transplant rejection medications in 2018, due to presence of the maximum number of living as well as deceased donors and better organ-preserving practices in the region. However, high costs and complex procedures would adversely affect the organ transplant rejection medications market during the forecast period. The organ transplant rejection medications market in Asia Pacific is projected to expand at a relatively high CAGR of 4.1% during the forecast period. Transplantation procedures vary substantially from region to region and country to country, due to factors such as difference in the rate of end-organ damage, economic differences in terms of ability to provide transplants or other treatments, cultural differences that can support or hinder organ donation and transplant, and reporting of legal transplants across regions.

    Major Market Players

    The report provides profiles of leading players operating in the global organ transplant rejection medications market. These include GlaxoSmithKline plc, Novartis AG, F. Hoffmann-La Roche Ltd., Astellas Pharma, Inc., Pfizer, Inc., AbbVie, Inc., Allergan plc, Bristol-Myers Squibb Company (BMS), and Sanofi.

    Novartis AG is a leading company that specializes in the development and manufacture of branded as well as generic pharmaceutical and biopharmaceutical drugs. It is evaluating the experimental Facilitating Cell Therapy (FCR001), which involves taking stem cells of a kidney donor and grafting them in the transplant recipient’s bone marrow. This combination would trick the recipient’s immune system by accepting the donated kidney as its own.

    Pfizer, Inc. is a global pharmaceutical company that develops, manufactures, and markets prescription medicines in 11 therapeutic segments, including cardiovascular, oncology, neuroscience, pain, and infectious diseases. The company offers a range of medicines and vaccines as well as consumer healthcare products for the prevention and treatment of infectious and chronic diseases for all age groups.

    More Trending Reports by Transparency Market Research –

    ECG Devices Market –

    https://www.prnewswire.com/news-releases/ecg-devices-market-to-gain-us-6-79-billion-by-2026--says-tmr-300813779.html

    Request For Coronavirus Infection Market Analysis –

    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16940


  • Organ Preservation Solutions Market  Trends and Growth Factors Analysis

    Transparency Market Research (TMR) (www.transpare) has published a new report titled, ‘Organ Preservation Solutions Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’. According to the report, the global Organ Preservation Solutions Market was valued at US$ 193.4 Mn in 2018 and is projected to expand at a CAGR of 10.5% from 2019 to 2027.?

    Overview

    • Organ Preservation solutions are used for preserving organs before transplantation surgeries. This solutions maintains organ viability, rapidly cool down the organ and minimizes cellular injury. This solutions enables the organ for proper storage, transportation, and transplantation into the recipient.
    • Europe dominated the global organ preservation solutions market in 2018 and the trend is anticipated to continue during the forecast period. Rise in organ failure and growing need of organ transplantation in the region are expected to drive the market in Europe.
    • North America is the second major revenue generating region in organ preservation solution market. As per Organ Donation Statistics, 36,528 organ transplantation were performed in the year 2018 in the United States. Also, more than 113,000 people in the United States, are in the waiting list in the July 2019 for organ transplantation.
    • Asia Pacific is likely to be a highly lucrative market for organ preservation solution expected to expand at a high CAGR during the forecast period.

    Planning To Lay Down Future Strategy? Request Brochure Of Organ Preservation Solutions Market 

    https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1786

    Rise in Organ Transplantation Procedures to Drive Market

    • Rise in incidences of organ failure in kidney, liver and heart patients across the globe is augmenting the demand for organ transplant procedures. This has further led to rise in the demand for organ preservation solutions that help maintain the organs’ viability from the time of donation to transplantation. Market growth for organ preservation solutions will also be propelled by the rise in the number of elderly people worldwide since, risk of organ failure in people of this age group is higher.
    • As per, American Society of Nephrology states, an aged patient’s body shows less graft rejection and that has led to increased preference for organ transplants by surgeons for them.

    Custodial HTK Segment to Dominate Market

    • Based on solution type, the global organ preservation solutions market has been Viaspan, Custodiol HTK, Renograf, Hypothermosol, Perfadex, Lifor, HBS Solution, siRNA Transplant Solutions, and others.
    • The Custodial HTK segment held major share of the global organ preservation solutions market in 2018 and the trend is anticipated to continue during the forecast period. The attributable factors are growing organ transplantation in which solutions are utilized to preserve various organs such as kidney, lungs, liver and pancreas. Also, it is a vintage preservation solution and hence has gained considerable popularity in the industry which has resulted in increasing preference for Custodiol over other solutions in the market.
    • For instance, Custodiol is utilized extensively for preserving kidneys according to the U.S. National Institute of Health (NIH) journal. Moreover, as per research, Custodiol solution is used for 2 million procedure in the Europe region.

    Hypothermic Perfusion Preservation Technique to be Highly Lucrative Segment

    • In terms of preservation technique, the global organ preservation solutions market has been divided into Hypothermic Perfusion Preservation, Static Cold Storage, and Others.
    • The static cold storage segment is a standard solution utilize for organ preservation, and hypothermic perfusion preservation is expected to grow at highest CAGR during forecast period. Few attributable factors includes the efficiency of hypothermic perfusion technique in continuous supply solution to the organ and hence prevents any tissue injury.

    To Obtain All-Inclusive Information On Forecast Analysis Of Organ Preservation Solutions Market  , Request A Discount

    https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1786

    Europe to Dominate Global Market

    • In terms of region, the global organ preservation solutions market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe dominated the global organ preservation solutions market in 2018, followed by North America.
    • Europe accounted for major share of the global organ preservation solutions Market in 2018, followed by North America owing to increase in organ transplantation surgeries in the region. Moreover, rising incidences of kidney, liver and other organ failure drives the need of transplant surgeries and increase the demand of organ preservation solutions in the market. Various countries of the region like Spain follow opt out policy where a person, if has not opted for denial of organ donation, will be considered as an organ donor after death (brain death) automatically. This increases the number of donors in the region and hence will drive the growth of the market.
    • The organ preservation solutions market in Asia Pacific is anticipated to expand at a highest CAGR from 2019 to 2027. This can be attributed to increasing awareness about the organ transplantation, technological advancement, and increasing demand of organ preservation solutions for the same. Rising incidences of death due to organ failure, rapid economic growth in developing economies such as India, China, Indonesia and others are another attributable factors for the market growth in the region.

    Competitive Landscape

    • The global organ preservation solutions market is consolidated in terms of number of players. Key players in the global market include
      • Dr. Franz Köhler Chemie GmbH
      • Bristol-Myers Squibb
      • XVIVO Perfusion AB
      • Teva Pharmaceutical Industries Ltd
      • BioLife Solutions, Inc.
      • ToleroTech, Inc.
    • Companies strive to maintain their leading position in the market by adopting various business strategies such as launch of innovative products and acquiring various competitors. Recent Merger & Acquisition strategy enabled companies to expand their product line and strengthen geographic presence across globe.

    More Trending Reports by Transparency Market Research –

    ECG Devices Market –

    https://www.prnewswire.com/news-releases/ecg-devices-market-to-gain-us-6-79-billion-by-2026--says-tmr-300813779.html

    Request For Coronavirus Infection Market Analysis –

    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16940


  • Tularemia Therapeutics Market - Major Factors Driving the Industry

    Tularemia: A Rare Form of Infectious Disease Primarily Affecting Mammals

    • Tularemia is a rare infectious disease caused by a bacterium called Francisella tularensis. The disease spreads in humans through several routes, including insect (tick and deer fly) bites and direct exposure to an infected animal.
    • Tularemia is also called rabbit fever or deer fly fever. Its general symptoms include fever, skin ulcer, chills, headache, eye pain, redness, throat pain, and mouth ulcer. Severe symptoms include dry cough, chest pain, difficulty in breathing, high fever, and pneumonia.
    • Tularemia spreads through various means such as insect bites, exposure to sick or dead animals, airborne bacteria, and contaminated food or water
    • Several preventive measures are adopted, especially by people who generally go for hiking, camping, or hunting animals. Use of antibiotics is an effective treatment of this disease.

    Report Overview @ https://www.transparencymarketresearch.com/tularemia-therapeutics-market.html

    Key Drivers and Restraints of Global Tularemia Therapeutics Market

    • Rise in the number of reported cases of tularemia and growing exposure of people to insects led by travelling to certain regions are some of the major factors driving the global tularemia therapeutics market. For instance, according to Centers for Disease Control and Prevention (CDC), a total of 93 cases of tularemia were reported in the U.S. in 2009, which rose to 229 in 2018.
    • Ongoing investigational therapy studies for tularemia is also a major factor fueling the global tularemia therapeutics market
    • Rise in awareness among people regarding the tularemia disease is also augmenting the global tularemia therapeutics market

    Planning To Lay Down Future Strategy? Request Brochure Of Tularemia Therapeutics Market

    https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75917

    Antibacterial Resistance to Hamper Market

    • Tularemia is primarily cured by antibiotics, which include tetracyclines, fluoproquinolones, and aminoglycosides. Antibacterial resistance is a major point of concern in prescribing these drugs. Several strains of bacteria are found to be resistant to these drugs. This factor can hamper the global tularemia therapeutics market.
    • Side-effects caused by these antibiotic drugs sometimes lead to serious complications, which is also restraining the global market

    Streptomycin: a More Popular Drug of Choice for Treatment of Tularemia

    • Based on drug, the global tularemia therapeutics market can be divided into streptomycin, gentamycin, doxycycline, ciprofloxacin, and others
    • Streptomycin is a more popular drug of choice for treatment of tularemia, due to high efficacy of this drug against the disease and its less side-effects
    • Ciprofloxacin is likely to be a promising segment of the global market during the forecast period. Patients who cannot tolerate aminoglycosides have better option of ciprofloxacin. Also, this drug is recommended for use in the treatment of community-acquired pneumonia.

    Ulceroglandular Tularemia Segment Dominates Global Market

    • In terms of type, the global tularemia therapeutics market can be divided into ulceroglandular tularemia, glandular tularemia, oculoglandular tularemia, oropharyngeal tularemia, pneumonic tularemia, and others
    • The ulceroglandular tularemia segment dominates the global market, due to high rate of incidence of this type of tularemia and its effective symptomatic relief by antibiotics

    To Obtain All-Inclusive Information On Forecast Analysis Of Tularemia Therapeutics Market , Request A Discount

    https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=75917

    Online Pharmacies a More Promising Segment

    • Based on distribution channel, the global tularemia therapeutics market can be classified into hospital pharmacies, retail pharmacies, and online pharmacies
    • The retail pharmacies segment leads the global market, due to easy availability of branded as well as generic drugs and easy accessibility to retail pharmacies for patients
    • Online pharmacies is likely to be a highly lucrative segment during the forecast period, owing to rising preference for online purchase by people and discounted rates of drugs offered by online stores

    North America to Lead Global Market for Tularemia Therapeutics

    • In terms of region, the global tularemia therapeutics market can be divided into: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
    • North America dominated the global tularemia therapeutics market in 2018, due to the large number of reported cases of tularemia, presence of bacterial strains in some parts of the region, and early adoption of treatment options in the region. For instance, as per the CDC data, a total of 55 cases of tularemia were reported in the Arkansas state of the U.S. alone in 2018, which is the maximum rate among all states.
    • Asia Pacific is projected to be a highly lucrative market for tularemia therapeutics during the forecast period, owing to anticipated increase in the number of reported cases of tularemia in the next few years, better diagnosis of tularemia, and growing awareness about the disease and its treatment in the region

    Key Manufacturers Operating in Global Market

    Key manufacturers operating in the global tularemia therapeutics market are:

    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Bayer AG
    • Mylan N.V.
    • Teva Pharmaceutical Industries Ltd.
    • Lupin Pharmaceuticals, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Glenmark Pharmaceuticals Limited
    • Apotex Inc.
    • Dr. Reddy’s Laboratories Ltd.

    More Trending Reports by Transparency Market Research –

    ECG Devices Market –

    https://www.prnewswire.com/news-releases/ecg-devices-market-to-gain-us-6-79-billion-by-2026--says-tmr-300813779.html

    Request For Coronavirus Infection Market Analysis –

    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16940


  • Acute Sensorineural Hearing Loss Treatment Market - Brief Analysis by Top Key Players

    Global Acute Sensorineural Hearing Loss Treatment Market: Introduction

    Acute sensorineural hearing loss occurs when the inner ear, the cochlea in the inner ear, or the nerve pathways between the ear and the brain get damaged. Audiometry tests can check human hearing more thoroughly and precisely. During these tests, an audiologist tests the patient’s hearing ability by using earphones. A series of different sounds and volume levels is sent to each ear individually. This helps determine the level at which hearing begins to fade.

    Report Overview @ https://www.transparencymarketresearch.com/acute-sensorineural-hearing-loss-treatment-market.html

    About 4,000 cases of acute sensorineural hearing loss are diagnosed every year in the U.S. The condition most commonly affects people aged between 30 and 60 years. About 50% of people in the U.S. are suffering from unilateral acute sensorineural hearing loss, wherein only one ear is affected. This condition can be recovered within two weeks with prompt treatment. About 15% of people with this condition have hearing loss that can gradually worsen over time. However, advancements in technology used for hearing aids and cochlear implants are helping improve communication for people affected by hearing loss.

    Planning To Lay Down Future Strategy? Request Brochure Of Acute Sensorineural Hearing Loss Treatment Market

    https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75913

    Key Drivers of Global Acute Sensorineural Hearing Loss Treatment Market

    Rapidly growing incidence of acute sensorineural hearing loss

    • The rate of incidence of sudden sensorineural hearing loss is 5–20 per 100,000 individuals. The actual rate of incidence of sudden sensorineural hearing loss may be higher than these estimates, as affected individuals that recover quickly do not opt for medical care. The two most common bacterial infections known to cause sudden sensorineural hearing loss in the U.S. are Lyme disease and syphilis. Lyme disease is endemic in North America. It is caused by infection by a spirochete called Borrelia burgdorferi, which is transmitted by the bite of deer ticks.

    Increase in geriatric population

    • Elderly population across the globe continues to grow at an unprecedented rate. Presently, 8.5% of people across the world (i.e. 617 million) are aged 65 years or above. In the U.S., approximately one in three people aged between 65 and 74 years has hearing loss and nearly 50% of people aged above 75 years have difficulty hearing. Having trouble hearing can make it hard to understand and follow doctor's advice; respond to warnings; and hear phones, doorbells, and smoke alarms. Hearing loss can also make it hard to enjoy talking with family and friends, leading to feeling of isolation. According to a new report titled ‘An Aging World: 2015’ published by International Population Reports, the percentage of elderly population is projected to increase to nearly 17% of the world’s population that is 1.6 billion by 2050. According to the National Institutes of Health, the number of people in the U.S. aged 65 years or above is anticipated to nearly double in the next three decades, from 48 million to 88 million by 2050.

    To Obtain All-Inclusive Information On Forecast Analysis Of Acute Sensorineural Hearing Loss Treatment Market , Request A Discount

    https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=75913

    Increasing noise pollution

    • Based on a study by CDC in 2011–12 involving hearing tests and interviews with participants, the National Institute on Deafness & Other Communication Disorders states that at least 10 million adults in the U.S. (i.e. 6%) are aged 70 years or below and 40 million (i.e. 24%) have hearing loss in one or both ears caused by exposure to loud noise.

    North America to Account for a Major Share of Global Acute Sensorineural Hearing Loss Treatment Market

    • North America is projected to account for a major share of the global acute sensorineural hearing loss treatment market during the forecast period. The market in the region is anticipated to expand at a rapid pace in the near future, primarily due to availability of developed health care infrastructure and continuous research activities for the development of advanced technologies in the region. North America is expected to be followed by Europe during the forecast period.
    • The acute sensorineural hearing loss treatment market in Asia Pacific is expected to expand at a high CAGR during the forecast period. This can be attributed to rise in the trend of preventive health care measures in the region.

    Key Players Operating in Global Market

    The global acute sensorineural hearing loss treatment market is highly consolidated, with the presence of a small number of key players. Several manufacturers hold a major share of the market in their respective regions. Leading players operating in the global acute sensorineural hearing loss treatment market are:

    • Pfizer
    • Bristol-Myers Squibb Company
    • Allergan
    • Watson Laboratories
    • Inapta Pharmaceuticals
    • Renate Pharmaceutical
    • Merck & Co Ltd
    • F. Hoffmann-La Roche Ltd.
    • Eli Lilly and Company
    • Novartis AG
    • GlaxoSmithKline Plc
    • Teva Pharmaceuticals

    More Trending Reports by Transparency Market Research –

    ECG Devices Market –

    https://www.prnewswire.com/news-releases/ecg-devices-market-to-gain-us-6-79-billion-by-2026--says-tmr-300813779.html

    Request For Coronavirus Infection Market Analysis –

    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16940


  • Congenital Adrenal Hyperplasia Market Development, Trends, Segmentations Analysis

    Congenital Adrenal Hyperplasia Market: Introduction

    • Congenital adrenal hyperplasia refers to a group of genetic conditions that affect the adrenal glands leading to low levels of cortisol and high levels of male hormones called androgens, causing development of male characteristics in females, and early puberty in both boys and girls. The milder and more common form of congenital adrenal hyperplasia (CAH) is called non-classic. The classic form, which is more severe, can be detected through newborn screening. Some forms of CAH can cause problems with normal growth and development in children and even be life-threatening.
    • The global incidence of congenital adrenal hyperplasia in newborns is roughly 1 in 16,000 to 1 in 20,000 population. The incidence in the U.S. is around 1 in 16,000 to 1 in 18,000 population.

    Report Overview @ https://www.transparencymarketresearch.com/congenital-adrenal-hyperplasia-market.html

    Key Drivers and Restraints of Global Congenital Adrenal Hyperplasia Market

    Government funding and support along with collaborative research with large pharmaceutical players is anticipated to boost the growth of the global market in the near future. In 2018, the International fund Raising for Congenital Adrenal Hyperplasia (IFCAH) launched eighth call for proposals, in association with ESPE.

    Planning To Lay Down Future Strategy? Request Brochure Of Congenital Adrenal Hyperplasia Market

    https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75911

    Classic Segment to Dominate Global Market

    • In terms of type, the classic segment accounted for major market share in 2018. The segment is expected to grow at a steady pace during the forecast period. It is likely to be driven by rise in prevalence of classic congenital adrenal hyperplasia across the globe. Classic congenital adrenal hyperplasia is the most prevalent form of congenital adrenal hyperplasia due to 21-hydroxylase deficiency, which is responsible for roughly 95% of cases. Classic congenital adrenal hyperplasia is of two types: simple virilizing and salt wasting. Salt wasting form of congenital adrenal hyperplasia leads to symptoms such as dehydration and hypotension in the first few weeks of life and can be life-threatening. The salt wasting congenital adrenal hyperplasia accounts for 70% of the classic congenital adrenal hyperplasia cases.

    Hospitals to Lead Global Congenital Adrenal Hyperplasia Market

    • The hospitals segment is likely to capture nearly half of the market share in terms of revenue by 2027. It is projected to be the most lucrative segment of the global congenital adrenal hyperplasia market during the forecast period. Governments are extending support and funding toward increasing the number of skilled surgeons. This in turn increases the number of hospitals offering surgeries and treatment for congenital adrenal hyperplasia. For instance, the International Fund Congenital Adrenal Hyperplasia (IFCAH) is a private fundraising organization that aims to promote academic research on congenital adrenal hyperplasia.
    • Well-established hospitals and health care infrastructure are anticipated to cater to the rise in demand for congenital adrenal hyperplasia treatment in North America during the forecast period. Developed countries are considered hubs for safe and effective surgeries. This perception will create opportunities in the congenital adrenal hyperplasia market in North America, followed by Europe. However, developing countries could present significant opportunities for investments and expansion for market players.
    • Asia Pacific is expected to be a potential market for congenital adrenal hyperplasia due to large patient pool and dense population. Growing medical tourism driven by government regulations favoring local players and relatively low surgery costs are likely to contribute to the lucrativeness of the congenital adrenal hyperplasia market in the region.
    • However, high cost continues to hamper the growth of the congenital adrenal hyperplasia market in developed as well as developing countries. Financial lucidity of consumers has made them independent enough to spend out-of-the-pocket on their health. However, cost of these surgeries and treatments is high even after an insurance cover, which is preventing the market from realizing its full potential.

    To Obtain All-Inclusive Information On Forecast Analysis Of Congenital Adrenal Hyperplasia Market , Request A Discount

    https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=75911

    Key Players Operating in Global Congenital Adrenal Hyperplasia Market

    Pharmaceutical companies in the global congenital adrenal hyperplasia market are increasingly investing in the research & development on congenital adrenal hyperplasia drugs.

    The global congenital adrenal hyperplasia market is moderately fragmented. Market players focus on strategic partnerships, collaborations, mergers, acquisitions, and product launches to increase market share. Leading companies operating in the global market are:

    • Emerge Health
    • Sentia Medical Sciences, Inc.
    • Neurocrine Biosciences, Inc.
    • Millendo Therapeutics, Inc.
    • Spruce Biosciences, Inc.
    • Thermo Fisher Scientific ( Life Technologies Corporation)
    • Adrenas Therapeutics, Inc.
    • Alder Biopharmaceuticals, Inc.

    More Trending Reports by Transparency Market Research –

    ECG Devices Market –

    https://www.prnewswire.com/news-releases/ecg-devices-market-to-gain-us-6-79-billion-by-2026--says-tmr-300813779.html

    Request For Coronavirus Infection Market Analysis –

    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16940


  • Microfluidic Immunoassay Market Segments, Leading Player, Application & Forecast Analysis

    Microfluidic Immunoassay Market: Overview

    • The immunoassay is one of the important analytical techniques based on molecular recognition between antibody and antigen that allows for detection of molecules with high specificity and sensitivity. Immunoassays are being widely used for the quantification of target molecules in many applications, such as proteomics, clinical diagnostics, pharmaceutical research, and basic biological investigations.
    • In recent years, the use of microfluidic chips for immunoassays has been extensively explored.  Combination of microfluidics and immunoassays provides a promising platform for various sensitive and automatic point-of-care (PoC) diagnostics.

    Report Overview @ https://www.transparencymarketresearch.com/microfluidic-immunoassay-market.html

    • Microfluidic systems, also termed as lab-on-a-chip and the micro total analysis system, have shown promising results in immunosensor platforms. Microfluidic immunosensors provide significant advantages over conventional immunoassay methods, such as a high surface-to-volume ratio for efficient mass transport in immunoreactions, thus allowing for fast analysis; a miniaturized micro channel dimension to minimize the consumption of samples and reagents; and automated integration with other functions, such as pumps, valves, detectors, and mixers to attain a point-of-care (PoC) goal.

    Planning To Lay Down Future Strategy? Request Brochure Of Microfluidic Immunoassay Market

    https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75841

    Key Drivers of Global Microfluidic Immunoassay Market

    • Advancements in microfluidic immunosensors, rise in burden of diseases, and need for novel diagnostic techniques are expected to drive the global microfluidic immunoassay market
    • Fast and progressive growth in the field of pharmaceutical and biotechnology drives the development of innovative and powerful sensing technique for detection and process optimization of biomolecules at very low concentrations. Microcantilever is one of the promising label-free techniques for biosensing applications, which has gained attention due to its fast response, small size, high sensitivity, and compatible integration into lab-on-a-chip devices.
    • Microfluidic immunosensors possess remarkable features that surpass those of conventional immunosensing systems. These features include operational automation, reduced consumption of reagents and samples, compact size, cheap unit cost, and low power consumption.
    • Increase in technological advances in instruments and label-free detection technologies and advantages of microfluidic immunosensors over conventional techniques are some of the factors anticipated to drive the global microfluidic immunoassay market during the forecast period

    North America to Hold Major Share of Global Microfluidic Immunoassay Market

    • North America is projected to account for a prominent share of the global market during the forecast period. Increase in research & development activities in the field of diagnostics, adoption of advanced testing techniques and presence of major players in life sciences industry, large number of research institutes, and growing need for new and improved therapies to address medical conditions, are expected to fuel the growth of the market in the region.
    • Economic growth in India, China, Brazil, Mexico, and other countries in Asia and Latin America has improved the health care infrastructure and accessibility to innovative products and health care services. Moreover, rise in incidence of non-communicable and infectious diseases along with aging population and increase in disposable income are expected to drive the microfluidics immunoassay market.  

    To Obtain All-Inclusive Information On Forecast Analysis Of Microfluidic Immunoassay Market , Request A Discount

    https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=75841

    Key Players Operating in Global Microfluidic Immunoassay Market

    Major players operating in the global microfluidic immunoassay market are:

    • Abbott Laboratories
    • F. Hoffmann-La Roche AG
    • Bio-Rad Laboratories
    • Agilent Technologies, Inc.
    • GE Healthcare
    • Nan?mix, Inc.
    • Micropoint Bioscience, Inc.
    • Biosurfit SA
    • Quidel Corporation

    More Trending Reports by Transparency Market Research –

    ECG Devices Market –

    https://www.prnewswire.com/news-releases/ecg-devices-market-to-gain-us-6-79-billion-by-2026--says-tmr-300813779.html

    Request For Coronavirus Infection Market Analysis –

    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16940


  • Microfluidic Immunoassay Market Segments, Leading Player, Application & Forecast Analysis

    Microfluidic Immunoassay Market: Overview

    • The immunoassay is one of the important analytical techniques based on molecular recognition between antibody and antigen that allows for detection of molecules with high specificity and sensitivity. Immunoassays are being widely used for the quantification of target molecules in many applications, such as proteomics, clinical diagnostics, pharmaceutical research, and basic biological investigations.
    • In recent years, the use of microfluidic chips for immunoassays has been extensively explored.  Combination of microfluidics and immunoassays provides a promising platform for various sensitive and automatic point-of-care (PoC) diagnostics.

    Report Overview @ https://www.transparencymarketresearch.com/microfluidic-immunoassay-market.html

    • Microfluidic systems, also termed as lab-on-a-chip and the micro total analysis system, have shown promising results in immunosensor platforms. Microfluidic immunosensors provide significant advantages over conventional immunoassay methods, such as a high surface-to-volume ratio for efficient mass transport in immunoreactions, thus allowing for fast analysis; a miniaturized micro channel dimension to minimize the consumption of samples and reagents; and automated integration with other functions, such as pumps, valves, detectors, and mixers to attain a point-of-care (PoC) goal.

    Planning To Lay Down Future Strategy? Request Brochure Of Microfluidic Immunoassay Market

    https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75841

    Key Drivers of Global Microfluidic Immunoassay Market

    • Advancements in microfluidic immunosensors, rise in burden of diseases, and need for novel diagnostic techniques are expected to drive the global microfluidic immunoassay market
    • Fast and progressive growth in the field of pharmaceutical and biotechnology drives the development of innovative and powerful sensing technique for detection and process optimization of biomolecules at very low concentrations. Microcantilever is one of the promising label-free techniques for biosensing applications, which has gained attention due to its fast response, small size, high sensitivity, and compatible integration into lab-on-a-chip devices.
    • Microfluidic immunosensors possess remarkable features that surpass those of conventional immunosensing systems. These features include operational automation, reduced consumption of reagents and samples, compact size, cheap unit cost, and low power consumption.
    • Increase in technological advances in instruments and label-free detection technologies and advantages of microfluidic immunosensors over conventional techniques are some of the factors anticipated to drive the global microfluidic immunoassay market during the forecast period

    North America to Hold Major Share of Global Microfluidic Immunoassay Market

    • North America is projected to account for a prominent share of the global market during the forecast period. Increase in research & development activities in the field of diagnostics, adoption of advanced testing techniques and presence of major players in life sciences industry, large number of research institutes, and growing need for new and improved therapies to address medical conditions, are expected to fuel the growth of the market in the region.
    • Economic growth in India, China, Brazil, Mexico, and other countries in Asia and Latin America has improved the health care infrastructure and accessibility to innovative products and health care services. Moreover, rise in incidence of non-communicable and infectious diseases along with aging population and increase in disposable income are expected to drive the microfluidics immunoassay market.  

    To Obtain All-Inclusive Information On Forecast Analysis Of Microfluidic Immunoassay Market , Request A Discount

    https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=75841

    Key Players Operating in Global Microfluidic Immunoassay Market

    Major players operating in the global microfluidic immunoassay market are:

    • Abbott Laboratories
    • F. Hoffmann-La Roche AG
    • Bio-Rad Laboratories
    • Agilent Technologies, Inc.
    • GE Healthcare
    • Nan?mix, Inc.
    • Micropoint Bioscience, Inc.
    • Biosurfit SA
    • Quidel Corporation

    More Trending Reports by Transparency Market Research –

    ECG Devices Market –

    https://www.prnewswire.com/news-releases/ecg-devices-market-to-gain-us-6-79-billion-by-2026--says-tmr-300813779.html

    Request For Coronavirus Infection Market Analysis –

    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16940


  • Proliferative Vitreoretinopathy Market Key Players, Industry Overview and Forecast Analysis

    Proliferative Vitreoretinopathy Market: Introduction

    • The proliferative vitreoretinopathy (PVR) process is analogous to the dynamic wound healing that leads to skin keloid formation. Retinal glial cells and macrophages could also play important roles by providing a scaffold for membrane formation and/or by releasing trophic factors. The surgical approach for PVR is generally the same for primary retinal detachments without membranes. The principal difference is that there is significantly more retinal traction in PVR, which is caused by membranes and bands rather than vitreous gel alone. PVR is currently the biggest obstacle to successful retinal reattachment surgery, accounting for nearly 75% of all primary surgical failures. PVR is characterized by growth and migration of preretinal or subretinal membranes. Iatrogenic tears are more common when removing anterior PVR (near the vitreous base). When tears occur or when PVR is difficult to remove with peeling alone, a relaxing retinectomy could be needed. Given the inflammatory nature of PVR, corticosteroids are considered to be primary therapeutic candidates when trying to prevent PVR.

    Report Overview @ https://www.transparencymarketresearch.com/proliferative-vitreoretinopathy-market.html

    Key Drivers of Global Proliferative Vitreoretinopathy Market

    Increase in Geriatric Population

    • The world’s geriatric population continues to increase at an unprecedented rate. Presently, 8.5% of the global population (617 million) is aged 65 and over. According to a new report, An Aging World: 2015, the percentage is projected to jump to nearly 17% of the global population by 2050 (1.6 billion). According to the National Institutes of Health, the U.S.’s 65-and-over population is anticipated to nearly double in the next three decades, from 48 million to 88 million by 2050. The global population of the “oldest old” - people aged 80 and older - is expected to more than triple between 2015 and 2050, increasing from 126.5 million to 446.6 million. The oldest old population in some countries in Asia and Latin America is likely to quadruple by 2050. 

    Planning To Lay Down Future Strategy? Request Brochure Of Proliferative Vitreoretinopathy Market

    https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75819

    Surge in incidence of Retinoblastoma

    • Proliferative vitreoretinopathy (PVR) occurs after retinal detachment and is a major complication of surgical reattachment of the retina, occurring in 3.9% to 13.7% of human patients. PVR is also a common complication following a number of ocular injuries, with the highest frequency after perforating and penetrating wounds, in which the incidence is 10% to 45%. Proliferative vitreoretinopathy is the biggest obstacle to successful retinal reattachment surgery, with a cumulative risk of approximately 5% to 10% of all retinal detachment repairs, accounting for around 75% of all primary surgical failures. 

    North America to Account for Major Share of Global Proliferative Vitreoretinopathy Market

    • North America is projected to account for major share of the global proliferative vitreoretinopathy market during the forecast period. The market in North America is anticipated to grow at a rapid pace, primarily due to structured reimbursement policies, developed health care infrastructure, and continuous research activities in developing advanced technologies. Favorable government policies and reimbursements provided by the government along with robust health care facilities are the major factors boosting the growth of the proliferative vitreoretinopathy market in North America.
    • The proliferative vitreoretinopathy market in Asia Pacific is expected to grow at a rapid pace during the forecast period. This can be attributed to increase in trend of preventive health care measures in the region.

    To Obtain All-Inclusive Information On Forecast Analysis Of Proliferative Vitreoretinopathy Market , Request A Discount

    https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=75819

    Key Players Operating in Global Proliferative Vitreoretinopathy Market

    The global proliferative vitreoretinopathy market is highly consolidated, due to strong presence of a few key players. Several manufacturers hold major share in the market in their respective regions. Leading players operating in the global proliferative vitreoretinopathy market are:

    • Novartis AG
    • Promedior, Inc.
    • RXi Pharmaceuticals Corp.
    • Allergan plc
    • Regeneron Pharmaceuticals, Inc.
    • Genentech, Inc.

    More Trending Reports by Transparency Market Research –

    ECG Devices Market –

    https://www.prnewswire.com/news-releases/ecg-devices-market-to-gain-us-6-79-billion-by-2026--says-tmr-300813779.html

    Request For Coronavirus Infection Market Analysis –

    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16940


  • T-cell Therapy Market - SWOT Analysis of Major Industry Segments

     

    Rise in Prevalence of Cancer Propelled T-cell Therapy Market

    • T-cell therapy includes using genetically engineered T-cells to produce an artificial T-cell receptor for application in immunotherapy.  Both the first two FDA-approved CAR-T therapies target the CD19 antigen, which is found on many types of B-cell cancers. Kymriah is approved to treat relapsed/refractory B-cell precursor acute lymphoblastic leukemia and Yescarta is approved to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

    Report Overview @ https://www.transparencymarketresearch.com/t-cell-therapy-market.html

    • Growing prevalence of cancer across the world and increase in cancer research & development drive the market. According to the WHO, the number of global cancer deaths is projected to increase by 45% between 2008 and 2030. It is also estimated that by 2030, approximately 10 to 11 million cases of cancers would be diagnosed each year in low- and middle-income countries.

    Planning To Lay Down Future Strategy? Request Brochure Of T-cell Therapy Market

    https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75857

    Key Drivers and Restraints of Global T-cell Therapy Market

    • Increase in investment in adoptive T-cell transfer approaches of disease treatment drives the market. Furthermore, technological advancements in manufacturing processes and developments in CAR T-cell therapy for solid tumors fuel the revenue generation. The approvals and clinical success of Kymriah and Yescarta opened new and encouraging avenues for developers of cellular immunotherapies.
    • High prices of therapies are likely to limit the market growth in the near future. The CAR T therapy costs range between US$ 373,000 and US$ 475,000 per infusion. The reimbursement gap remains unsustainable and is a huge impediment to patient access. In the U.S., CMS recently raised reimbursement of the total cost of CAR T-cell therapies from 50% to 65%, effective from 2020.

    CAR T-cell Therapy Estimated to Dominate Global T-cell Therapy Market

    • Based on type, the global T-cell therapy market can be divided into: CAR T-cell Therapy, T-cell Receptor (TCR)-based, and Tumor Infiltrating Lymphocytes (TIL)-based
    • The CAR T-cell therapy segment dominated the global T-cell therapy market in terms of revenue generation in 2018 and is expected to lead the position during the forecast period. Large number of research institutions and companies are doing clinical studies with different CAR-T products that often target the same condition.
    • In 2018, Kymriah, which is a T-cell therapy for the treatment of acute lymphoblastic leukemia, was manufactured for more than 300 patients intended to be used across 11 countries and 35 certified treatment centers. On the other hand, by June 2018, around 61 cancer centers were authorized for Yescarta administration to patients, which is the first CAR T therapy for adults living with certain types of non-Hodgkin lymphoma. Rise in number of research & development activities boosts the market growth.

    To Obtain All-Inclusive Information On Forecast Analysis Of T-cell Therapy Market , Request A Discount

    https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=75857

    Solid Tumors Segment to Witness Highest Growth

    • Based on indication, the global T-cell therapy market can be divided into: Hematologic Malignancies and Solid Tumors. The hematologic malignancies segment is sub-segmented into lymphoma, leukemia, and myeloma. The solid tumors segment is further segmented into melanoma, brain & central nervous system, liver cancer, and others.
    • In terms of indication, the hematologic malignancies segment dominated the global T-cell therapy market in 2018. CAR T-cell therapy has efficiently proven its effectiveness for hematologic malignancies, especially diffuse B-cell lymphoma (DBCL). Over 25,000 new cases of diffuse large B-cell lymphoma (DLBCL) are diagnosed annually in the U.S., representing an incidence rate of 6.9 per 100,000.
    • However, solid tumors offer tenfold greater opportunity than hematological cancers with possibly 1.3 million cancer patients annually. Effective and affordable CAR-T for solid tumors treatment offers benefits to patients and substantial investment returns to market entities.

    North America to Dominate Global T-cell Therapy Market

    • In terms of region, the global T-cell therapy market can be divided into: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
    • In terms of revenue, North America dominated the T-Cell therapy market in 2018, followed by Europe, due to high number of sponsors from the U.S. for clinical trials, large number of research institute presence, and the U.S. FDA approval of CAR T-cell therapeutics in the U.S. and Canada. In August 2017, the first chimeric antigen receptor T-cell (CAR-T cell) therapy was approved for the market in the U.S. for targeted cancer immunotherapy, and CAR-T cell therapy developers have recently gained entry into the market in Europe as well.
    • Asia Pacific is expected to grow at the highest CAGR during the forecast period. Rise in number of clinical trials pertaining to CAR T-cell therapies and increase in number of diseases are anticipated to boost the growth of the market in this region.

    Key Manufacturers Operating in Market

    The global T-cell therapy market was highly fragmented in 2018. Key manufacturers operating in the global market are:

    • Novartis AG
    • Gilead Sciences, Inc.
    • TCR2 Therapeutics Inc.
    • Sorrento Therapeutics, Inc.
    • Fate Therapeutics
    • Merck KGaA
    • Pfizer
    • Amgen
    • Celgene Corporation

    More Trending Reports by Transparency Market Research –

    ECG Devices Market –

    https://www.prnewswire.com/news-releases/ecg-devices-market-to-gain-us-6-79-billion-by-2026--says-tmr-300813779.html

    Request For Coronavirus Infection Market Analysis –

    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16940


  • Postpartum Depression (PPD) Treatment Market: Pin-Point Analysis for Changing Competitive Dynamics

    Postpartum Depression (PPD) Treatment: Introduction

    • Postpartum depression (PPD) affects some women after giving birth to a baby. Key symptoms are anxiety, changes in sleeping & eating patterns, sadness, low energy, and irritability.

    Report Overview @ https://www.transparencymarketresearch.com/postpartum-depression-ppd-treatment-market.html

    • PPD develops within 4 weeks to 6 weeks after giving birth or could appear after a few months of delivery. It does not affect all pregnant women; however, is seen mostly after 3 months to 6 months of childbirth. This could lead to symptoms affecting psychological behavior such as low mood that lasts for longer than a week, crying, reduced motivation, and feeling of inadequacy.
    • Physical changes of pregnancy, complicated or difficult labor, loneliness, a history of mental health problems, and hormonal changes are the other factors contributing to PPD
    • Postpartum depression (PPD) treatment includes counseling, help of support groups, and medications

    Planning To Lay Down Future Strategy? Request Brochure Of Postpartum Depression (PPD) Treatment Market

    https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75839

    Key Drivers of Global Postpartum Depression (PPD) Treatment Market

    • The global postpartum depression (PPD) treatment market is primarily driven by launch of new products, recent product approvals from regulatory bodies such as the Food and Drug Administration (FDA), and increase in awareness about PPD
    • In March 2019, the FDA granted approval for Zulresso (brexanolone) injection for the treatment of postpartum depression (PPD) in adult women. The drug is manufactured by Sage Therapeutics, Inc., a pharmaceutical company based in the U.S.
    • Additionally, non-government organizations undertake a number of awareness programs for PPD which enable women to gain knowledge about the condition and avoid complications during child birth

    Selective Allosteric Modulators of Gamma-Aminobutyric Acid Type A (GABA (A)) Receptor Segment to Capture Significant Market Share

    • Based on drug class, the global postpartum depression (PPD) treatment market can be classified into selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitor (SNRI), and selective allosteric modulators of gamma-aminobutyric acid type A (GABA(A)) receptor
    • The selective allosteric modulators of gamma-aminobutyric acid type A (GABA(A)) receptor segment is anticipated to capture significant share of the global postpartum depression (PPD) treatment market during the forecast period, owing to launch of branded drugs in this drug class and rise in adoption of new therapies for PPD.

    Branded Segment to Account for Major Share of Global Postpartum Depression (PPD) Treatment Market

    • In terms of drug type, the global postpartum depression (PPD) treatment market can be bifurcated into branded and generics. The branded segment is projected to account for the largest market share due to increase in availability of branded drugs. However, high cost of these drugs is likely to restrain the segment.

    Oral Segment to Offer Significant Opportunities in Global Postpartum Depression (PPD) Treatment Market

    • Based on route of administration, the global postpartum depression (PPD) treatment market can be categorized into oral and intravenous
    • The oral segment is expected to account for major share of the global postpartum depression (PPD) treatment market by 2027. The segment is projected to be driven by high availability of orally administered drugs in the form of tablets, capsules, and oral solution.

    To Obtain All-Inclusive Information On Forecast Analysis Of Postpartum Depression (PPD) Treatment Market , Request A Discount

    https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=75839

    Hospital Pharmacies Segment to Capture Significant Share of Global Postpartum Depression (PPD) Treatment Market

    • In terms of distribution channel, the global postpartum depression (PPD) treatment market can be divided into hospital pharmacies, retail pharmacies, and online pharmacies. The online pharmacies segment is anticipated to offer significant opportunities, especially in the developed countries in North America and Europe.

    North America to Dominate Global Postpartum Depression (PPD) Treatment Market

    • In terms of region, the global postpartum depression (PPD) treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the global postpartum depression (PPD) treatment market during the forecast period.
    • Rise in prevalence of postpartum depression in the U.S. and strengthening R&D efforts by market players are likely to drive the market in North America during the forecast period
    • According to the PostpartumDepression.org, 70% to 80% of women in the U.S. are likely to experience postpartum depression

    Key Players Operating in Global Postpartum Depression (PPD) Treatment Market

    The global postpartum depression (PPD) treatment market is highly fragmented, with a large number of domestic players accounting for major market share. Key players operating in the global postpartum depression (PPD) treatment market are:

    • Sage Therapeutics
    • Pfizer, Inc.
    • Allergan
    • Eli Lilly and Company
    • Sebela Pharmaceuticals, Inc.
    • GlaxoSmithKline
    • Mylan N.V.

    More Trending Reports by Transparency Market Research –

    ECG Devices Market –

    https://www.prnewswire.com/news-releases/ecg-devices-market-to-gain-us-6-79-billion-by-2026--says-tmr-300813779.html

    Request For Coronavirus Infection Market Analysis –

    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16940


  • Genetic Testing Services Market Estimated to Expand at a Robust CAGR by 2025

    The global genetic testing services market was valued over US$ 33,500.0 Mn in 2016 and is projected to register a compounded annual growth rate (CAGR) of over 7.6% from 2017 to 2025, according to a new report published by Transparency Market Research (TMR) titled “Genetic Testing Services Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”. The report suggests that the rising demand for innovative technologies and increasing research & development activities in the field of genetics are likely to drive the genetic testing services market in the next few years (from 2017 to 2025). North America and Europe are projected to dominate the global genetic testing services market in the next few years, owing to rise in the adoption of genetic services and increase in health care spending in these regions. Asia Pacific is projected to be a rapidly expanding market for genetic testing services from 2017 to 2025.

    This can be attributed to increase in medical tourism, adoption of genetic testing services, and rise in awareness about benefits of genetic testing in developed countries such as Japan and Australia. Development of innovative tests and value-added services by service providers is expected to fuel the global genetic testing services market during the forecast period. The Asia Pacific genetic testing services market is expected to register the highest CAGR of 7%–8% from 2017 to 2025.

    Planning To Lay Down Future Strategy? Request Brochure Of Genetic Testing Services Market

    https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=10235

    High Prevalence of Cancer to fuel Global Market

    High prevalence of cancer such as breast cancer is one of the driving factors for the global genetic testing services market. Increasing early detection of breast cancer by testing of the BRC gene is driving the global market. Chronic diseases such as diabetes and other cardiovascular diseases require identifying of high-risk patients and implementation of disease management, which is made possible by genetic testing. This factor is projected to drive the global genetic testing services market during the forecast period. Furthermore, combination of health care IT with genetics and increase in health care spending are some of the factors estimated to propel the global market during the forecast period. Lack of awareness about genetic services in developing countries is one of the factors likely to restrain the global market between 2017 and 2025.

    Predictive & Presymptomatic Testing and Hospital-based Segments expected to dominate the Global Market

    The report offers detailed segmentation of the global genetic testing services market based on test type, service provider, and application. Among test types, the predictive & presymptomatic testing segment is poised to account for a leading share of the global market from 2017 to 2025. Factors attributable to the major share held by the segment in the global market include early detection of diseases such as cancer, detection of asymptomatic diseases, and identifying the gene-associated risks. The segment held over 20% share of the global market in 2016, in terms of revenue. Based on service provider, the global genetic testing services market has been segmented into hospital-based laboratories, diagnostic laboratories, specialty clinics, and others. The hospital-based laboratories segment dominated the global market accounting for over 40% of the market share in 2016. The specialty clinics segment is expected to expand at a rapid pace during the forecast period, due to value-added services offered by these clinics.

    To Obtain All-Inclusive Information On Forecast Analysis Of Genetic Testing Services Market , Request A Discount

    https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=10235

    Oncology Segment dominates the Market, followed by Others Segment

    Based on application, the global genetic testing services market has been classified into oncology, infectious diseases, autoimmune diseases, and others. The oncology segment is expected to hold the largest share of the global market from 2017 to 2025, due to high prevalence of cancer and increase in awareness about early detection of cancer. The segment held approximately 40% share of the global market in 2016. The others segment held the second-largest share of the market in 2016, owing to increase in the prevalence of rare diseases and rise in genetic testing in the field of obstetrics.

    High Incremental Opportunity in Asia Pacific

    In terms of geography, the global genetic testing services market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the global genetic testing services market in 2016 and is projected to continue to dominate the market from 2017 to 2025. The market in the region is projected to expand at a CAGR of over 7% from 2017 to 2025. Well-established health care infrastructure and strong support from public and private sectors in terms of reimbursements are factors responsible for the largest share held by North America in the global genetic testing services market. Rise in awareness about the disease prevention has led to improvement in the disease diagnosis, which is anticipated to drive the market in the region during the forecast period. Europe is projected to hold the second-largest share of the global genetic testing services market during the forecast period. The market in the region is estimated to expand at a CAGR of 7%–8% from 2017 to 2025. Rising health care expenditure in the region, increasing prevalence of autoimmune diseases, and entry of new players are some of the factors fueling the genetic testing services market in Europe.

    Asia Pacific is a rapidly expanding market for genetic testing services, which is likely to expand at a CAGR of over 8% during the forecast period. Population explosion and high prevalence of infectious diseases in Asia Pacific are some of the major factors boosting the market in the region. Australia, Japan, India, and China are potential markets for genetic testing services in the region. The market in India is expected to expand at a rapid CAGR during the forecast period, due to rise in disposable income and increase in funding for R&D in the country. The genetic testing services market in Middle East & Africa is expected to expand at a CAGR of 6%–7% during the forecast period. Mandatory health care insurance in Gulf countries and high prevalence of infectious diseases in countries in Africa augment the market in the region. Brazil also offers high growth potential to the genetic testing services market, as several diagnostic manufacturers are focused on establishing facilities in the country.

    More Trending Reports by Transparency Market Research –

    Lithotripsy Device Market –

    https://www.prnewswire.com/news-releases/increasing-prevalence-of-kidney-stones-to-drive-growth-of-global-lithotripsy-device-market-to-valuation-worth-us0-98-bn-by-2026-end-transparency-market-research-301003584.html

    Request For N99 Face Mask Market Analysis –

    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=76379


  • Wound Debridement (Wound Cleaning) Market Pegged for Robust Expansion by 2025

    The global wound debridement (wound cleaning) market is anticipated to exhibit a positive growth trajectory, according to a Transparency Market Research (TMR) study. Featuring an intensely fragmented business landscape, the global wound debridement market comprises several strong players. High competition exists between vendors operating in the wound debridement market. 

    In order to gain precedence over competitors, vendors in the global wound debridement market are seen leveraging several organic and inorganic growth strategies. Expansions, mergers and acquisitions, expansion of product portfolio, and collaborations are some of the key strategies adopted by market players. A prime example is Crawford Healthcare’s acquisition by Acelity L.P. the company aims at expanding their product offering in order to strengthen its market position. 

    Another prominent approach considered by vendors in the global wound debridement market is the launch of novel and advanced products. This is a leading trend leveraged by players to gain traction in the global wound debridement (wound cleaning) market in the coming years. 

    Planning To Lay Down Future Strategy? Request Brochure Of Wound Debridement (Wound Cleaning) Market

    https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=35036

    TMR analysts forecast the global wound debridement market to reach a value of US$ 3,044.8 mn by 2025, from an estimated worth of US$ 1,750 mn in 2016. From the forecast period 2017 to 2025, the global wound debridement market is estimated to grow at a 6.5% CAGR.   

    Rise in Incidence of Chronic Diseases Drives Wound Debridement Market 

    The escalating incidence of chronic ailment such as diabetes is a key factor fuelling the global wound debridement (wound cleaning) market. Diabetics are likely to suffer from wounds that do not heal easily. This may lead to severe wound infections. With the growing number of diabetic cases across the globe, wound debridement is gaining traction. The International Diabetes Federation reports that by 2040, diabetes incidence will is expected to reach 642.0 million. Wound debridement is highly significant in patients with diabetes, and will incite the global wound debridement market. In addition to this, the importance of wound debridement is being realized for other situations/medical emergencies such as burns, removal of necrotic tissue, etc. which will fuel the global wound debridement (wound cleaning) market further. 

    To Obtain All-Inclusive Information On Forecast Analysis Of Wound Debridement (Wound Cleaning) Market , Request A Discount

    https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=35036

    Presence of Infrastructure, Skilled Professionals to Boost Growth 

    With a rise in the hospitalization cases, surgeries, and incidence of chronic wounds, the healthcare industry is rapidly progressing. Increased investments are being made in the sector, and aware patients and their families are ready to spend higher amounts on healthcare. The number of healthcare professionals, especially specialists, is rising. The presence of skilled professionals combined with higher spending on healthcare is likely to augment demand in the global wound debridement market in the coming years. 

    Emergence of Advanced Therapies to Vitalize Wound Debridement Market 

    Advanced therapies are coming into play which is expected to turn tides in the global wound debridement market. The introduction of single use negative pressure therapy (NPWT), especially in homecare settings, is gaining traction. This too, will support the wound debridement market growth dynamics over the forthcoming years. Further, the introduction of ultrasonic devices is likely to boost the wound debridement market. Ultrasonic devices offer benefits such as the capacity to differentiate between non-viable and viable tissues. These devices further aid in destroying biofilms and bacteria without causing damage to blood vessels. This is anticipated to provide an impetus to the global wound debridement (wound cleaning) market in coming years. 

    More Trending Reports by Transparency Market Research –

    Lithotripsy Device Market –

    https://www.prnewswire.com/news-releases/increasing-prevalence-of-kidney-stones-to-drive-growth-of-global-lithotripsy-device-market-to-valuation-worth-us0-98-bn-by-2026-end-transparency-market-research-301003584.html

    Request For N99 Face Mask Market Analysis –

    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=76379


  • DNA Test Kits Market to Register Substantial Expansion by 2027

    Transparency Market Research (TMR) has published a new report titled, “DNA Test Kits Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027”. According to the report, the global DNA test kits market was valued at US$ 747.0 Mn in 2018 and is projected expand at a CAGR of 23.4% from 2019 to 2027. Increase in demand for DNA kits for ancestry testing, Increasing awareness among people regarding use of DNA test kits for disease risk assessment and rise in popularity of direct-to-consumer testing are anticipated to drive the global DNA test kits market.

    Planning To Lay Down Future Strategy? Request Brochure Of DNA Test Kits Market

    https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=53934

    Increase in Demand for Ancestry Testing to Drive Market

    • Demand for ancestry testing using saliva-based or cheek swab DNA test kits is rising in the developed countries in North America and Europe. There is rapid increase in the number of users of DNA test kits for ancestry and health & fitness. The number of people interested in knowing about their ancestors and family tree has increased is also anticipated to increase the demand for DNA test kits, especially in developed countries across the globe
    • Moreover, increase in number of applications of direct-to-consumer genetic testing and rise in demand for DNA testing for health & fitness are the other factors anticipated to drive the DNA test kits market
    • During Christmas and Black Friday, companies offer high discounts and offers on DNA testing services and people gift DNA test kits to their relatives. Furthermore, companies offer diet, health & fitness for free or as a part of subscription leading to increase in number of customers using DNA test kits. Therefore, boom in ancestry testing in North America is likely to boost the growth of the DNA test kits market.
    • Key players in the global DNA test kits market such as DNAFit and My Inner Go offer a number of DNA testing services to meet the demand for DNA test kits for fitness. These provide tailored fitness and weight management advice to the customers.
    • Additionally, strategic approaches such as product launch, marketing efforts, distribution agreements and others are anticipated to propel the global DNA test kits market

    Asia Pacific Offers Significant Opportunities

    • Along with the U.S., the DNA test kits market is booming in countries such as China and Japan. These genetic tests have become popular through social media and other online platforms. This is anticipated to boost the growth of the DNA test kits market.
    • Recent acquisitions by companies in China have supported the growth of DNA test kits market in the region. For instance, Prenetics acquired DNAFit in April 2018.
    • Moreover, people are concerned about increase in lifestyle diseases such as obesity and diabetes. Rise in awareness about preventive care measures to tackle the burden of diseases has led to an increase in the number of people interested in DNA test kits for diet & nutrition and health & fitness.
    • Other factor driving the DNA test kits market in the region is increase in knowledge about processing and analysis of DNA sample by the companies
    • Furthermore, a number of startups in China and Japan have launched new products for fitness testing considering an increase in genetic testing for diet and fitness

    To Obtain All-Inclusive Information On Forecast Analysis Of DNA Test Kits Market , Request A Discount

    https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=53934

    New Product Launch and Strengthening Distribution Channels: Key Strategies Adopted by Key Players in DNA Test Kits Market

    • The report also provides profiles of leading players operating in the global DNA test kits market. These include Ancestry, 23andMe, Inc., MyHeritage Ltd., Gene by Gene, Ltd., Living DNA Ltd., National Geographic Partners, LLC, Helix OpCo, LLC, Veritas, FitnessGenes, and EasyDNA.
    • The leading companies in the global DNA test kits market are focused on strengthening distribution channel and product portfolio expansion to gain market share. In November 2018, Helix OpCo, LLC launched a new DNA test kits for ancestry and wellness DNA testing with customer access to two embedded apps, Ancestry Basics and Wellness Basic.
    • In August 2016, Ancestry entered into a collaboration with Quest Diagnostics to expand consumer DNA test kits portfolio and expand its presence in DNA test kits market

    More Trending Reports by Transparency Market Research –

    Lithotripsy Device Market –

    https://www.prnewswire.com/news-releases/increasing-prevalence-of-kidney-stones-to-drive-growth-of-global-lithotripsy-device-market-to-valuation-worth-us0-98-bn-by-2026-end-transparency-market-research-301003584.html

    Request For N99 Face Mask Market Analysis –

    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=76379


  • Orthobiologics Market to Reflect Impressive Growth Rate by 2026

    Transparency Market Research (TMR) has published a new report titled, “Orthobiologics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global orthobiologics market was valued at US$ 4.8 Bn in 2017 and is projected expand at a CAGR of 5.5% from 2018 to 2026. High prevalence of sports injuries and arthritis and rise in prevalence of trauma injuries are anticipated to augment the global market between 2018 and 2026. 

    Orthobiologics comprise tissue and bone replacement materials used to expedite healing and recovery of ligaments, tendons, muscles, and bones. Orthobiologics are integral part of orthopedic surgical procedures, as these assist in rapid recovery of joints, bones, and muscles post-surgical procedure and reduce healing time. Orthobiologics comprise products such as synthetic bone substitutes, bone cement, allografts, stem cells, and others. Rise in the global geriatric population increases the prevalence of chronic orthopedic diseases such as arthritis and osteoporosis. Moreover, increase in cases of sports injury and trauma is likely to propel the global orthobiologics market. However, orthobiologics is a new technology and in a nascent stage of adoption. Limited reimbursement support for orthobiologics such as stem cells and allografts is anticipated to restrain the global market. High cost of bone grafts creates difficulty in obtaining reimbursement. Additionally, extensive clinical studies for safety of bone healing products is a constraint for obtaining reimbursement for orthobiologics. Moreover, procedure developed from existing treatment, coding options, and lack of data to differentiate the products are the various reimbursement challenges. This hampers the growth of the global orthobiologics market. 

    Planning To Lay Down Future Strategy? Request Brochure Of Orthobiologics Market

    https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1747

    The report offers detailed segmentation of the global orthobiologics market based on product, application, and end-user. The market has also been segmented based on region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). Introduction of new orthobiologics which reduce the healing & recovery time and offer better biocompatibility with low or null adverse effects is likely to drive the global orthobiologics market. Orthobiologics are relatively new, hence reimbursement is less compared to other options. 

    Allografts Segment to Account for Leading Share and Witness Strong Growth

    In terms of product, the viscosupplements segment accounted for leading share of the global market in 2017 and the trend is anticipated to continue during the forecast period. Moreover, increase in the number of regulatory approvals for allograft orthobiologics products is projected to contribute to the growth of the segment during the forecast period. High biocompatibility of allografts and better efficacy are expected to drive the uptake of these products from 2018 to 2026. The stem cell therapy segment is likely to expand at the second fastest CAGR during the forecast period. The segment is anticipated to gain market share from 2018 to 2026. Surge in the number of trauma cases is likely to boost the growth of the segment. 

    Emerging Technologies in Orthobiologics to Propel Market

    Emerging technologies in orthobiologics is projected to boost the growth of the global orthobiologics market during the forecast period. 3D printed implant technology helps reduce surgery time, provides better stability, and improves clinical outcome for orthopedic surgical procedures. SpineVision’s 3D laser printed HEXANIUM TLIF for spine surgery helps reduce risk of subsidence in disc height in the post-operative period. Tornier’s BioFiber Surgical Mesh is used in the treatment of rotator cuff and other tendon injuries. SeaSpine’s OsteoBallast is a resorbable mesh used in the treatment of spinal fusion. It helps to prevent graft migration and simplifies graft placement. 

    To Obtain All-Inclusive Information On Forecast Analysis Of Orthobiologics Market , Request A Discount

    https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1747

    North America to be Most Lucrative Orthobiologics Market

    North America has a large number of orthobiologics products approved for treatment of various orthopedic conditions. High adoption of advanced therapies in the treatment of orthopedic conditions and favorable reimbursement policies for orthobiologics contributed to North America’s leading market share. Large geriatric population, increase in incidence of trauma and injuries, and demand for quality health care are likely to contribute to the region’s leading share during the forecast period. 

    Product Launches by Key Players and Patent Approvals to Boost Market

    The report also provides profiles of leading players operating in the global orthobiologics market. These include Medtronic, DePuy Synthes (Johnson & Johnson), Sanofi, Seikagaku Corporation, Stryker, MTF Biologics, Bioventus, Artthrex, Zimmer Biomet, RTI Surgical, Inc., Alphatec Spine, Inc., Exactech, Inc., Globus Medical, Inc., and Integra LifeSciences. Launch of new products and focus on developing technologically advanced products by companies, and patent approvals are expected to drive the global market during the forecast period. In September 2018, NuVasive, Inc. launched a new product line for Propel DBM. To broaden the product line, the company provided Propel DBM gel and Propel DBM Putty with osteoconductive property which help to promote bone growth. In March 2018, Synergy Biomedical LLC received clearance from Therapeutic Goods Clearance (TGA) in Australia for BioSphere Putty, a synthetic bone graft product that helps bone healing. 

    More Trending Reports by Transparency Market Research –

    Lithotripsy Device Market –

    https://www.prnewswire.com/news-releases/increasing-prevalence-of-kidney-stones-to-drive-growth-of-global-lithotripsy-device-market-to-valuation-worth-us0-98-bn-by-2026-end-transparency-market-research-301003584.html

    Request For N99 Face Mask Market Analysis –

    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=76379


  • Auto-injectors Market Poised to Expand at a Robust Pace by 2020

    The demand within the global market for auto-injectors is projected to trace an upward graph over the forthcoming years, predicts Transparency Market Research (TMR). The market players in the global market for auto-injectors have been introducing new and innovative strategies in order to establish their supremacy on global landscape. While the leading players making new leaps in business by manufacturing advanced products for drug injection, the smaller market players are focusing on effective pricing and product positioning. The presence of multitudes of small, medium, and large-scale vendors gives a mark of fragmentation to the global market for auto-injectors.

    Mergers and acquisitions are anticipated to be the most sought after strategies of the vendors operating in the global market for auto-injectors. While mergers help the large market vendors in expanding their consumer base, the smaller market players can sustain in the market by merging themselves with larger vendors. The new players entering the global auto-injectors market are expected to concentrate on capturing the regional market before advancing towards the larger regions. Strategic alliances, partnerships, and collaborations are also expected to be the defining strategies within the global market for auto-injectors.

    Planning To Lay Down Future Strategy? Request Brochure Of Auto-injectors Market

    https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4199

    The global market for auto-injectors is projected to reach a value of US$2.5 bn by 2020-end from a value of US$665.0 mn in 2013. Thereby, the CAGR of the global market for auto-injectors is expected to settle at 18.60% over the period between 2014 and 2020. Based on geography, the market for auto-injectors in North America is expected to outdo all other regional markets. On the basis of therapeutic application, the rheumatoid arthritis segment is projected to attract the highest demand.

    Heavy Incidence of Chronic Diseases to Propel Market Demand

    The demand within the global market for auto-injectors has been escalating on account of the rising incidence of chronic diseases such as cancer, diabetes, pulmonary disorders, and rheumatoid arthritis. The administration of drugs for the treatment of all the aforementioned drugs is done through auto-injectors, thus, enhancing the growth prospects of the global market. Auto-injectors are easy to handle and inject, which makes it easy for individual to self-administer drugs and medications. This is also an important standpoint that has led to the growth of the global market for auto-injectors in recent times. Furthermore, the availability of auto-injectors that can help in injecting hormonal pills, insulin, and several reactive drugs into the body has also aided market growth.

    To Obtain All-Inclusive Information On Forecast Analysis Of Auto-injectors Market , Request A Discount

    https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=4199

    Cases of Duplication to Hamper Market Growth

    Despite the effectiveness of self-injectors in administering doses of medications into the body, the emergence of several cases of duplicated injectors has challenged the growth of the global market. However, the favourable medical reimbursements policies of several regional governments are expected to keep bolstering demand within the global market for self-injectors. Furthermore, intensive research and development meant to produce better-performing injectors is also expected to be a major contributor to market growth in the years to come. The availability of self-injectors that do not cause any pain to the individuals has also created commendable growth opportunities within the global market for auto-injectors.

    More Trending Reports by Transparency Market Research –

    Lithotripsy Device Market –

    https://www.prnewswire.com/news-releases/increasing-prevalence-of-kidney-stones-to-drive-growth-of-global-lithotripsy-device-market-to-valuation-worth-us0-98-bn-by-2026-end-transparency-market-research-301003584.html

    Request For N99 Face Mask Market Analysis –

    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=76379


  • Optical Imaging Market Foreseen to Grow Exponentially by 2020

    Canon, Inc., Bioptigen, Inc., ChemImage Corporation, Carl Zeiss AG, Heidelberg Engineering GmbH, Headwall Photonics, Inc., Michelson Diagnostics Ltd., NIDEK CO., LTD., St. Jude Medical, Inc., Optovue, Inc., and Topcon Medical Systems are to name a few of the prominent participants in the global optical imaging market. Banking upon cutting-edge research and development to build more effective and innovative optical imaging devices such companies have come to hold considerable shares in the market. On account of their constant thrust on product development, the market is expected to rise at a healthy clip in the near term.

    Such crucial trends have been unraveled by Transparency Market Research in one of its latest reports on the market for optical imaging. Our team of in-house experts who prepared the report predict the market to rise at a solid 10.80% CAGR over the course of the forecast period starting from 2014 and ending in 2020. Rising at this pace, it projects the market’s value to become US$2.1 bn by the end of 2020.

    Based on technology, the global market for optical imaging can be classified into optical coherence tomography (OCT), photoacoustic tomography (PAT), near infrared spectroscopy (NIRS), and hyperspectral imaging (HSI). Among them, the segment of OCT accounts for a gargantuan share in the market. From a geographical standpoint, North America at present accounts for a leading share in the market. This is because of the significant uptake of optical imaging technologies in a range of applications such as dentistry, ophthalmology, and dermatology in the region. In addition, a large pool of elderly who are afflicted with several health issues have also upped the demand for the product.

    Planning To Lay Down Future Strategy? Request Brochure Of Optical Imaging Market

    https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2093

    Optical Imaging See Uptake Due to their Ability to Reduce Exposure to Harmful Radiation

    Optical imaging, an upcoming and promising technology, is fast gaining traction because of its ability to prevent disease and bring about accurate diagnosis and treatment. They can be used in operating rooms, offices, and even one’s bedside. Such flexibility has majorly fuelled their uptake. Optical imaging are seen fast supplanting radiological imaging techniques. This is because of the myriad ways in which it steals a march over the latter. The most prominent among them is the usage of non-ionizing radiation which considerably lowers the patients’ exposure to harmful radiation. In addition, optical imaging has the ability to differentiate among soft tissues, and also between native soft tissues and tissue labeled with either exogenous or endogenous contrast media. Further, the process is highly amenable to multimodal imaging. Such unique perceived benefits are leading to swift sales of the product, thereby benefitting the market.

    To Obtain All-Inclusive Information On Forecast Analysis Of Optical Imaging Market , Request A Discount

    https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=2093

    Uses in Oncology Majorly Fuels Market

    Optical imaging finds application in a range of areas such as dentistry, ophthalmology, dermatology, neurology, cardiology, oncology, and biotechnology and research. Currently, the segment of oncology is majorly driving demand in their market. Apart from that, rising occurrence of eye, skin, teeth, and other various other organ related diseases are also serving to drive adoption of the devices. Constant product development too has positively impacted the market for optical imaging.

    More Trending Reports by Transparency Market Research –

    Lithotripsy Device Market –

    https://www.prnewswire.com/news-releases/increasing-prevalence-of-kidney-stones-to-drive-growth-of-global-lithotripsy-device-market-to-valuation-worth-us0-98-bn-by-2026-end-transparency-market-research-301003584.html

    Request For N99 Face Mask Market Analysis –

    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=76379


  • Home Blood Pressure Monitoring Devices Market Estimated to Flourish by 2027

    Transparency Market Research (TMR) has published a new report on the home blood pressure monitoring devices market for the forecast period of 2019–2027. According to the report, the global home blood pressure monitoring devices market was valued at ~ US$ 1 Bn in 2018, and is projected to expand at a CAGR of ~ 6% from 2019 to 2027.

    Planning To Lay Down Future Strategy? Request Brochure Of Home Blood Pressure Monitoring Devices Market

    https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=70611

    Global Home Blood Pressure Monitoring Devices Market: Overview

    • Blood pressure measurement is a way of measuring how much force is being exerted on the walls of the blood vessels when blood flows through them. The two basic measuring units of blood pressure are systolic and diastolic.
    • A joint scientific statement from the American Heart Association, the American Society of Hypertension, and the Preventive Cardiovascular Nurses Association stated that, self-measurement of blood pressure at home has been shown to be useful in eliminating the white coat effect, and multiple readings can be taken over a prolonged period of time.
    • Growth of the global home blood pressure measurement market is attributed to the rise in the awareness about the advantages of self-measurement through several campaigns, such as 'Because I Say So', and the availability of affordable blood pressure monitors at online stores.
    • North America dominated the global home blood pressure monitoring devices market in 2018, and the trend is anticipated to continue during the forecast period. This is attributed to the larger user base of new advanced products such as wrist monitors, which come at a high price.
    • However, the increase in the number of local manufacturers that is creating a pricing pressure in the market is likely to hamper the growth of the global home blood pressure monitors market in North America in the latter half of the forecast period. Asia Pacific is expected to be a highly lucrative market for home blood pressure monitors during the forecast period.

    Rise in Awareness about Advantages of Home BP Machines and Launch of New Advanced Home BP Monitors to Drive Market

    • Technological advancements in the field of healthcare has brought about significant changes in health care diagnostics, treatment, and clinical research & development. This is a major factor driving the global home blood pressure monitoring devices market.
    • Developments in digital blood pressure monitors which help to connect the devices and send data directly to a doctor have led to new monitoring techniques for better treatment.
    • New wearable blood pressure monitors such as HeartGuide, where patients can keep a close watch on their blood pressure anytime and anywhere, are helpful in preventing heart diseases and strokes. Hence, technological developments in blood pressure monitors are propelling the global home blood pressure monitoring devices market.
    • Additionally, rise in the awareness about advantages such as reduction in white coat effect of self-measurement or home blood pressure measurement through various campaigns conducted by the International Society of Hypertension increases the number of users of home blood pressure monitors.

    To Obtain All-Inclusive Information On Forecast Analysis Of Home Blood Pressure Monitoring Devices Market , Request A Discount

    https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=70611

    Upper Arm Monitor Reagents to Dominate Market

    • In terms of product, the global home blood pressure monitoring devices market has been classified into upper arm monitors, wrist monitors, and accessories. The upper arm monitors segment dominated the global home blood pressure monitoring devices market in 2018, and the trend is likely to continue during the forecast period because of the high patient preference for these devices due to an easy operating mode.

    Online Stores to be a Promising Distribution Channel

    • In terms of distribution channel, the global home blood pressure monitoring devices market has been divided into hospital pharmacies, retail pharmacies, online stores, and others (distributor, departmental stores, etc.) 
    • The online stores segment is expected to be a highly lucrative segment of the global home blood pressure monitoring devices market during the forecast period. The segment is likely to be driven by the availability of a wide range of blood pressure monitors and low pricing.

    North America a prominent Home Blood Pressure Monitoring Devices Market

    • Geographically, the global home blood pressure monitoring devices market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the global home blood pressure monitoring devices market in 2018, followed by Europe. The region accounted for a major share of the global home blood pressure monitoring devices market in 2018, owing to the high user base of home-based blood pressure monitors.
    • The home blood pressure monitoring devices market in Asia Pacific is projected to expand at a high CAGR from 2019 to 2027. This can be attributed to the large patient population, especially in countries such as India and China, where patients prefer to buy blood pressure devices for self-measurement.

    Blood Pressure Monitoring Devices Market: Competitive Landscape

    • OMRON Corporation, A&D Company, Limited, Beurer GmbH, and Hill-Rom, Inc. are the leading players in the global home blood pressure monitoring devices market, and hold a majority market share.
    • The global home blood pressure monitoring devices market is fragmented in terms of number of players. Key players in the global home blood pressure monitoring devices market include OMRON Corporation, A&D Company, Limited, Hill-Rom, Inc., SunTech Medical, Inc., Rossmax International Ltd., Qardio, Inc., Koninklijke Philips N.V., Beurer GmbH, Spengler SAS, and American Diagnostic Corporation. Wide distribution network, new product development, and mergers & acquisitions are the key strategies followed by these major players to gain a competitive advantage in the global home blood pressure monitoring devices market.

    More Trending Reports by Transparency Market Research –

    Lithotripsy Device Market –

    https://www.prnewswire.com/news-releases/increasing-prevalence-of-kidney-stones-to-drive-growth-of-global-lithotripsy-device-market-to-valuation-worth-us0-98-bn-by-2026-end-transparency-market-research-301003584.html

    Request For N99 Face Mask Market Analysis –

    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=76379


  • Patient Engagement Solutions Market to Witness an Outstanding Growth by 2023

    A new report by Transparency Market Research (TMR) states that the competitive landscape of the global market for the patient engagement solutions market exhibit highly fragmented structure, thanks to the large number of regional and global players. Most of the players in the global patient engagement solutions are largely focused on developing product portfolio and to strengthen their presence across the globe. The study also offers few prominent players operating in the global patient engagement solutions market such as Athenahealth Inc., Cerner Corp., Orion Health, Axial Exchange, Allscripts Inc., and McKesson Corp. Additionally, most of the company are providing technology based software solution as well as innovative software, which are mainly focused on bolstering patient’s engagement market. On the basis of such solution, the players are likely to gain a competitive advantage over others.

    As per Transparency Market Research (TMR), the global market for patient engagement solutions held an opportunity worth at US$6.66 bn in 2014. This market is likely to touch at least US$34.94 bn by 2023. The staggering growth in collection of revenue has been predicted to take place with a meteoric 23.0% CAGR from the period ranging between 2015 till 2023.

    Planning To Lay Down Future Strategy? Request Brochure Of Patient Engagement Solutions Market

    https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4506

    Massive Participation of the Patients-Doctor Drives Growth

    High engagement by the patient engagement solution to maintain their healthcare data could projected to drive the growth of this market in coming years. The patient engagement solution also offers improvised interaction among the medical team and the patient. This is one of the important factors positively influencing the growth of the market in near future. Technology advancement is another factor that helps the healthcare sector to provide necessary information to their patient in order to manage their health and to actively participate. Additionally, high demand for meaningful conversation among the patients and doctors is projected to drive the demand of the global market for patient engagement solution in near future.

    On the other hand, Increasing concern about maintain a privacy of data both in electronic forum as well as verbal form, could likely to hinder the growth of the global market for patient engagement solution. Moreover, increasing inclination of healthcare provider and patient involvement towards reimbursement process is likely to hamper the growth of the market in near future. While increasing government initiative and private organization to improve the quality service by doctor is likely to propel the opportunity of this market in coming years.   

    To Obtain All-Inclusive Information On Forecast Analysis Of Patient Engagement Solutions Market , Request A Discount

    https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=4506

    Rising Government Reforms Likely To Dominate the Patients Engagement Market in North America

    The study provides the global market for the patient engagement market in terms of geographical spread across the North America. Due to transformation of government reforms, and rising number of better healthcare services and changed payment method based on incentive are some of the factor propelling the growth in the patient engagement solution in the North America. The study highlight the fact that North America is likely to remain the leading market during the course of forecast period.

    More Trending Reports by Transparency Market Research –

    Lithotripsy Device Market –

    https://www.prnewswire.com/news-releases/increasing-prevalence-of-kidney-stones-to-drive-growth-of-global-lithotripsy-device-market-to-valuation-worth-us0-98-bn-by-2026-end-transparency-market-research-301003584.html

    Request For N99 Face Mask Market Analysis –

    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=76379


connect